| Tran Nam Le, MD | |
|
250 E 200 S Rm 1202, Salt Lake City, UT 84111-2472 | |
| (801) 581-3841 | |
| Not Available |
| Full Name | Tran Nam Le |
|---|---|
| Gender | Female |
| Speciality | General Practice |
| Location | 250 E 200 S Rm 1202, Salt Lake City, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194212258 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 12454160-1205 (Utah) | Secondary |
| 208D00000X | General Practice | S8201 (Texas) | Primary |
| Entity Name | Signify Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689158487 PECOS PAC ID: 3274895263 Enrollment ID: O20210225002062 |
News Archive
Researchers with the Cincinnati Cancer Center (CCC) and the University of Cincinnati (UC) Cancer Institute have discovered a new regulation for the cancer-causing protein KRas which may help with the development of targeted therapies for patients with a KRas mutation.
Nonin Medical, Inc., the inventor of finger pulse oximeters and a leader in noninvasive medical monitoring, announced today that the company has donated six Onyx 9500 finger pulse oximeters to the Evangelistic International Ministries (EIM) for use at the Hospital Centro Socorro De Lo Alto in the remote village of Sula, Honduras.
Pacira Pharmaceuticals, Inc. today announced the publication of data from a placebo-controlled, pivotal Phase 3 trial of EXPAREL (bupivacaine liposome injectable suspension), a non-opioid local analgesic that was recently approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.
A new study reports that vaginal estradiol tablets just might be what's needed to relieve vulvovaginal problems and improve overall quality of life.
Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tran Nam Le, MD 250 E 200 S Rm 1202, Salt Lake City, UT 84111-2472 Ph: (801) 581-3841 | Tran Nam Le, MD 250 E 200 S Rm 1202, Salt Lake City, UT 84111-2472 Ph: (801) 581-3841 |
News Archive
Researchers with the Cincinnati Cancer Center (CCC) and the University of Cincinnati (UC) Cancer Institute have discovered a new regulation for the cancer-causing protein KRas which may help with the development of targeted therapies for patients with a KRas mutation.
Nonin Medical, Inc., the inventor of finger pulse oximeters and a leader in noninvasive medical monitoring, announced today that the company has donated six Onyx 9500 finger pulse oximeters to the Evangelistic International Ministries (EIM) for use at the Hospital Centro Socorro De Lo Alto in the remote village of Sula, Honduras.
Pacira Pharmaceuticals, Inc. today announced the publication of data from a placebo-controlled, pivotal Phase 3 trial of EXPAREL (bupivacaine liposome injectable suspension), a non-opioid local analgesic that was recently approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.
A new study reports that vaginal estradiol tablets just might be what's needed to relieve vulvovaginal problems and improve overall quality of life.
Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.
› Verified 3 days ago
Dr. Walaa F. R. Abdelmoaty, MBCHB General Practice Medicare: Medicare Enrolled Practice Location: 250 E 200 S Rm 1202, Salt Lake City, UT 84111 Phone: 801-581-3841 | |
Dr. R. Heather Macalma, M.D. General Practice Medicare: Medicare Enrolled Practice Location: 250 E 200 S Rm 1202, Salt Lake City, UT 84111 Phone: 801-581-2121 | |
Dr. Linda Miller, General Practice Medicare: May Accept Medicare Assignments Practice Location: 675 E 2100 S, Salt Lake City, UT 84106 Phone: 800-366-1884 Fax: 801-487-8197 | |
Crystal Rose Lenz, D.O. General Practice Medicare: Not Enrolled in Medicare Practice Location: Eccless Institute Of Human Genetics: 15 N Medical Dr Rm, Space Base Delta 1, Salt Lake City, UT 84112 Phone: 801-581-2121 | |
Dr. Wallace Harold Ring, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 3125 Kennedy Dr., 1003, Salt Lake City, UT 84108 Phone: 801-581-0146 | |
Michael U. Hoerner, MD General Practice Medicare: Medicare Enrolled Practice Location: Helix: 30 N Mario Capecchi Rm 2s100, Salt Lake City, UT 84112 Phone: 801-581-2121 | |
Dr. Chad Chenoweth, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 1512 E 3115 S, Salt Lake City, UT 84106 Phone: 801-205-4112 |